David Proudman
Education
M.P.H., health policy and management, University of California, Berkeley; M.Biochem., molecular and cellular biochemistry, Oxford University
Summary of Experience
Mr. Proudman is a health economist with over a decade of experience in the US and global biopharmaceutical industry, specializing in economic modeling and market access strategy. His health economic modeling projects at Analysis Group have included cost-effectiveness and budget impact models, indirect treatment comparisons and evidence generation strategy, reimbursement submissions, and preparation for early scientific advice. In the area of market access, Mr. Proudman has performed primary and secondary research to synthesize and validate value messaging and pricing. He has worked in a number of disease areas, particularly oncology, central nervous system, cardiovascular, immunology, and ophthalmology. Prior to joining Analysis Group, Mr. Proudman was director of research and head of health care and technology at a global growth investment fund. He has also worked as a data scientist at the UCSF Center for Healthcare Value; as a lecturer in health economics and finance at the University of California, Berkeley; and as a project manager on observational data projects at NICE’s Centre for Health Technology Evaluation in the UK.
-
Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use
Journal of Medical Economics, 2022
2022Proudman D, DeVito NC, Belinson S, Allo MA, Morris ED, Signorovitch J, Patel AK
-
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
Advances in Therapy, 2022
2022Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K
-
Burden of central nervous system complications in sickle cell disease: A systematic review and meta-analysis
Pediatric Blood & Cancer, 2022
2022Lee S, Lucas S, Proudman D, Nellesen D, Paulose J, Sheehan VA
-
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers
PharmacoEconomics (2021) 39:619–625
2021 -
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
Journal of Managed Care & Specialty Pharmacy, 2021
2021Patwardhan P, Proudman D, Allen J, Lucas S, Nellesen D
-
June 14, 2021
-
June 7, 2021
-
June 4, 2021
-
April 13, 2021